Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Ingrid Fricke-Galindo & Ramcés Falfán-Valencia. (2022) Current pharmacogenomic recommendations in chronic respiratory diseases: Is there a biomarker ready for clinical implementation?. Expert Review of Respiratory Medicine 16:11-12, pages 1145-1152.
Read now
Read now
Timothy E Albertson, Willis S Bowman, Richart W Harper, Regina M Godbout & Susan Murin. (2019) Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 1251-1265.
Read now
Read now
Gaetano Caramori, Paolo Ruggeri, Paolo Casolari, Kian Fan Chung, Giuseppe Girbino & Ian M. Adcock. (2017) Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 11:12, pages 955-967.
Read now
Read now
Mario Malerba, Alessandro Radaeli, Paolo Montuschi & Jaymin B. Morjaria. (2016) Vilanterol trifenatate for the treatment of COPD. Expert Review of Respiratory Medicine 10:7, pages 719-731.
Read now
Read now
Sabrina Nickel, Caoimhe G. Clerkin, Mohammed Ali Selo & Carsten Ehrhardt. (2016) Transport mechanisms at the pulmonary mucosa: implications for drug delivery. Expert Opinion on Drug Delivery 13:5, pages 667-690.
Read now
Read now
Rashmi Mehta, Kelly Hardes, Noushin Brealey, Lee Tombs, Andrew Preece & Dennis Kelleher. (2015) Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 15-23.
Read now
Read now
Maria Gabriella Matera, Paola Rogliani, Barbara Rinaldi & Mario Cazzola. (2015) Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology 8:1, pages 35-41.
Read now
Read now
Mario Malerba, Jaymin Bhagwanji Morjaria & Alessandro Radaeli. (2014) Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD – role of umeclidinium/vilanterol. International Journal of Chronic Obstructive Pulmonary Disease 9, pages 687-695.
Read now
Read now
Andrea Segreti, Luigino Calzetta, Paola Rogliani & Mario Cazzola. (2014) Umeclidinium for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 8:6, pages 665-671.
Read now
Read now
Emer Kelly. (2014) Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology 7:4, pages 403-413.
Read now
Read now
Articles from other publishers (19)
Chukwunonso K. Nwabufo & Reina Bendayan. (2022) Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs. Trends in Pharmacological Sciences 43:12, pages 1041-1054.
Crossref
Crossref
Roy Pleasants. 2020. Cardiac Considerations in Chronic Lung Disease. Cardiac Considerations in Chronic Lung Disease
161
212
.
Yan Li, Huafang Li, Yucheng Sheng, Xin Du, Yuhui Yao, Xian Luo & Peiming Ma. (2019) Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults. Clinical Pharmacology in Drug Development 8:6, pages 721-733.
Crossref
Crossref
Carsten Ehrhardt, Per Bäckman, William Couet, Chris Edwards, Ben Forbes, Markus Fridén, Mark Gumbleton, Ken-Ichi Hosoya, Yukio Kato, Takeo Nakanishi, Mikihisa Takano, Tetsuya Terasaki & Ryoko Yumoto. (2017) Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs. Journal of Pharmaceutical Sciences 106:9, pages 2234-2244.
Crossref
Crossref
Han Ni, Aung Htet & Soe Moe. (2017) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2017:6.
Crossref
Crossref
Kesavan Suresh Babu & Jaymin Bhagwanji Morjaria. (2017) Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Therapeutic Advances in Chronic Disease 8:4-5, pages 81-91.
Crossref
Crossref
Editorial Article. (2016) Therapeutic strategy to prevent acute exacerbations of chronic obstructive pulmonary disease: clinical guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (Part 2). PULMONOLOGIYA 26:3, pages 267-291.
Crossref
Crossref
Roy A. Pleasants, Tiansheng Wang, Jinming Gao, Huilin Tang & James F. Donohue. (2016) Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis. Drugs 76:3, pages 343-361.
Crossref
Crossref
Johanna J. Salomon, Yohannes Hagos, Sören Petzke, Annett Kühne, Julia C. Gausterer, Ken-ichi Hosoya & Carsten Ehrhardt. (2015) Beta-2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1. Molecular Pharmaceutics 12:8, pages 2633-2641.
Crossref
Crossref
Gerard J. Criner, Jean Bourbeau, Rebecca L. Diekemper, Daniel R. Ouellette, Donna Goodridge, Paul Hernandez, Kristen Curren, Meyer S. Balter, Mohit Bhutani, Pat G. Camp, Bartolome R. Celli, Gail Dechman, Mark T. Dransfield, Stanley B. Fiel, Marilyn G. Foreman, Nicola A. Hanania, Belinda K. Ireland, Nathaniel Marchetti, Darcy D. Marciniuk, Richard A. Mularski, Joseph Ornelas, Jeremy D. Road & Michael K. Stickland. (2015) Prevention of Acute Exacerbations of COPD. Chest 147:4, pages 894-942.
Crossref
Crossref
Chaoying Hu, Jingying Jia, Kelly Dong, Linda Luo, Kai Wu, Rashmi Mehta, Jack Peng, Yan Ren, Annette Gross & Hui Yu. (2015) Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial. PLOS ONE 10:3, pages e0121264.
Crossref
Crossref
Hannah A. Blair & Emma D. Deeks. (2014) Umeclidinium/Vilanterol: A Review of Its Use as Maintenance Therapy in Adults with Chronic Obstructive Pulmonary Disease. Drugs 75:1, pages 61-74.
Crossref
Crossref
Rashmi Mehta, Kelly Hardes, Dennis Kelleher, Andrew Preece, Lee Tombs & Noushin Brealey. (2014) Effects of Moderate Hepatic Impairment on the Pharmacokinetic Properties and Tolerability of Umeclidinium and Vilanterol in Inhalational Umeclidinium Monotherapy and Umeclidinium/Vilanterol Combination Therapy: An Open-Label, Nonrandomized Study. Clinical Therapeutics 36:7, pages 1016-1027.e2.
Crossref
Crossref
Lesley J. Scott & Philip Hair. (2014) Umeclidinium/Vilanterol: First Global Approval. Drugs 74:3, pages 389-395.
Crossref
Crossref
Panayiotis A. Procopiou, Victoria J. Barrett, Keith Biggadike, Peter R. Butchers, Andrew Craven, Alison J. Ford, Stephen B. Guntrip, Duncan S. Holmes, Sara C. Hughes, Anne E. Jones, Brian E. Looker, Peter J. Mutch, Mark Ruston, Deborah Needham & Claire E. Smith. (2013)
Discovery of a Rapidly Metabolized, Long-Acting β
2
Adrenergic Receptor Agonist with a Short Onset Time Incorporating a Sulfone Group Suitable for Once-Daily Dosing
. Journal of Medicinal Chemistry 57:1, pages 159-170.
Crossref
Crossref
Johanna J. Salomon, Carsten Ehrhardt & Ken-ichi Hosoya. (2014) The Verapamil Transporter Expressed in Human Alveolar Epithelial Cells (A549) Does Not Interact with β2-Receptor Agonists. Drug Metabolism and Pharmacokinetics 29:1, pages 101-104.
Crossref
Crossref
A. Prakash, K.S. Babu & J.B. Morjaria. (2013) Novel anti-cholinergics in COPD. Drug Discovery Today 18:21-22, pages 1117-1126.
Crossref
Crossref
Ghaith Al-Jayyoussi, Daniel F. Price, Danielle Francombe, Glyn Taylor, Mathew W. Smith, Chris Morris, Chris D. Edwards, Peter Eddershaw & Mark Gumbleton. (2013) Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: A study in ex vivo lung models using chemical inhibition and genetic knockout. Journal of Pharmaceutical Sciences 102:9, pages 3382-3394.
Crossref
Crossref
Johanna J Salomon, Pauline Galeron, Nanette Schulte, Paul R Morow, Diana Severynse-Stevens, Hanno Huwer, Nicole Daum, Claus-Michael Lehr, Anthony J Hickey & Carsten Ehrhardt. (2013)
Biopharmaceutical
in vitro
characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis
. Therapeutic Delivery 4:8, pages 915-923.
Crossref
Crossref